Corcoran RB, Dias-Santagata D, Bergethon Ok, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote Acquired Resistance to MEK inhibitors in Most cancers cells harboring the BRAF V600E mutation. Sci Sign. 2010;3(149):ra84.
Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, et al. BRAF mutation is continuously current in sporadic colorectal Most cancers with methylated hMLH1, however not in Hereditary Nonpolyposis Colorectal Most cancers. Clin Most cancers Res. 2004;10(1):191–5.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human most cancers. Nature. 2002;417(6892):949–54.
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Results of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal most cancers: a retrospective consortium evaluation. Lancet Oncol. 2010;11(8):753–62.
Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, et al. Medical sequencing defines the genomic Panorama of Metastatic Colorectal Most cancers. Most cancers Cell. 2018;33(1):125–e1363.
Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, et al. BRAF V600E Mutant Colorectal Most cancers subtypes based mostly on Gene expression. Clin Most cancers Res. 2017;23(1):104–15.
Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway: new ideas of activation. Biol Cell. 2001;93(1–2):53–62.
Grothey A, Fakih M, Tabernero J. Administration of BRAF-mutant metastatic colorectal most cancers: a evaluate of remedy choices and evidence-based tips. Ann Oncol. 2021;32(8):959–67.
Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, et al. Molecular markers establish subtypes of stage III colon most cancers related to affected person outcomes. Gastroenterology. 2015;148(1):88–99.
Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, et al. Non-V600 BRAF mutations outline a clinically distinct molecular subtype of metastatic colorectal Most cancers. J Clin Oncol. 2017;35(23):2624–30.
Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in most cancers evolution and remedy. Sem Most cancers Biol. 2022;85:123–54.
Fu L, Chen S, He G, Chen Y, Liu B. Focusing on Extracellular Sign-regulated protein kinase 1/2 (ERK1/2) in Most cancers: an replace on pharmacological small-molecule inhibitors. J Med Chem. 2022;65(20):13561–73.
Yaeger R, Corcoran RB. Focusing on alterations within the RAF–MEK pathway. Most cancers Discov. 2019;9(3):329–41.
Jin H, Huang X, Pan Q, Ma N, Xie X, Wei Y, et al. The EIF3H-HAX1 axis will increase RAF-MEK-ERK signaling exercise to advertise colorectal most cancers development. Nat Commun. 2024;15(1):2551.
Ma W, Chen Y, Xiong W, Li W, Xu Z, Wang Y, et al. STOML2 interacts with PHB via activating MAPK signaling pathway to advertise colorectal Most cancers proliferation. J Experimental Clin Most cancers Res. 2021;40(1):359.
Ciombor KK, Strickler JH, Bekaii-Saab TS, Yaeger R. BRAF-Mutated Superior Colorectal Most cancers: a quickly altering Therapeutic Panorama. J Clin Oncol. 2022;40(24):2706–15.
Prahallad A, Solar C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon most cancers to BRAF(V600E) inhibition via suggestions activation of EGFR. Nature. 2012;483(7387):100–3.
Nakayama I, Hirota T, Shinozaki E. BRAF Mutation in Colorectal cancers: from prognostic marker to Targetable Mutation. Cancers (Basel). 2020;12(11):3236.
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI adopted by FOLFOX6 or the reverse sequence in superior colorectal most cancers: a randomized GERCOR research. J Clin Oncol. 2004;22(2):229–37.
Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, managed trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line remedy of metastatic colorectal most cancers: outcomes from the BICC-C research. J Clin Oncol. 2007;25(30):4779–86.
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Part III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in contrast with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line remedy for metastatic colorectal most cancers: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.
Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, et al. Part II pilot research of Vemurafenib in sufferers with metastatic BRAF-Mutated colorectal Most cancers. JCO. 2015;33(34):4032–8.
Gomez-Roca CA, Delord J, Robert C, Hidalgo M, von Moos R, Arance A, et al. 535P – encorafenib (Lgx818), an oral braf inhibitor, in sufferers (pts) with Braf V600E Metastatic Colorectal Most cancers (Mcrc): outcomes of dose growth in an Open-Label, section 1 research. Ann Oncol. 2014;25:iv182.
van der Meel R, Fens MHAM, Vader P, van Solinge WW, Eniola-Adefeso O, Schiffelers RM. Extracellular vesicles as drug supply programs: classes from the liposome area. J Management Launch. 2014;195:72–85.
Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, et al. Exosomes facilitate therapeutic concentrating on of oncogenic KRAS in pancreatic most cancers. Nature. 2017;546(7659):498–503.
Ai Y, Tian Y, Qiao J, Wang C, Li H. Yin-Yang philosophy for the design of anticancer drug supply nanoparticles. Biomater Transl. 2024;5(2):144–56.
Cao Z, Liu J, Yang X. Deformable nanocarriers for enhanced drug supply and most cancers remedy. Exploration. n/a(n/a):20230037.
Avruch J, Zhang XF, Kyriakis JM. Raf meets Ras: finishing the framework of a sign transduction pathway. Developments Biochem Sci. 1994;19(7):279–83.
Wang Y, Loree JM, Yu C, Tschautscher M, Briggler AM, Overman MJ, et al. Distinct impacts of KRAS, NRAS and BRAF mutations on survival of sufferers with metastatic colorectal most cancers. JCO. 2018;36(15suppl):3513–3513.
Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, et al. Mutant V600E BRAF will increase Hypoxia Inducible Issue-1α expression in Melanoma. Most cancers Res. 2007;67(7):3177–84.
Kang HB, Fan J, Lin R, Elf S, Ji Q, Zhao L, et al. Metabolic rewiring by oncogenic BRAF V600E hyperlinks ketogenesis pathway to BRAF-MEK1 signaling. Mol Cell. 2015;59(3):345–58.
Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, et al. Prevention of Dietary-Fats-Fueled Ketogenesis attenuates BRAF V600E Tumor Progress. Cell Metabol. 2017;25(2):358–73.
Hertzman Johansson C, Egyhazi Brage S. BRAF inhibitors in most cancers remedy. Pharmacol Ther. 2014;142(2):176–82.
Ruan W, Zhai Y, Yu Ok, Wu C, Xu Y. Coated microneedles mediated intradermal supply of octaarginine/BRAF siRNA nanocomplexes for anti-melanoma remedy. Int J Pharm. 2018;553(1–2):298–309.
Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira Ok, et al. Inhibition of development and invasive means of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene. 2004;23(36):6031–9.
Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, et al. Focusing on V600EB-Raf and Akt3 utilizing nanoliposomal-small interfering RNA inhibits cutaneous melanocytic Lesion Growth. Most cancers Res. 2008;68(18):7638–49.
Jadhav LA, Mandlik SK. Nanocarriers in pores and skin most cancers remedy: rising drug supply approaches and improvements. Nano TransMed. 2025;4:100068.
Esmaeili Y, Bidram E, Bigham A, Atari M, Nasr Azadani R, Tavakoli M, et al. Exploring the evolution of tissue engineering methods over the previous decade: from cell-based methods to gene-activated matrix. Alexandria Eng J. 2023;81:137–69.
Tao SC, Yuan T, Zhang YL, Yin WJ, Guo SC, Zhang CQ. Exosomes derived from mir-140-5p-overexpressing human synovial mesenchymal stem cells improve cartilage tissue regeneration and forestall osteoarthritis of the knee in a rat mannequin. Theranostics. 2017;7(1):180–95.
Wang X, Zhang H, Bai M, Ning T, Ge S, Deng T, et al. Exosomes function nanoparticles to ship anti-mir-214 to reverse chemoresistance to cisplatin in gastric Most cancers. Mol Ther. 2018;26(3):774–83.
Lou G, Music X, Yang F, Wu S, Wang J, Chen Z, et al. Exosomes derived from mir-122-modified adipose tissue-derived MSCs enhance chemosensitivity of hepatocellular carcinoma. J Hematol Oncol. 2015;8(1):122.
Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm. 2008;354(1–2):56–62.
Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wooden MJA. Supply of siRNA to the mouse mind by systemic injection of focused exosomes. Nat Biotechnol. 2011;29(4):341–5.
ichiro Ohno S, Takanashi M, Sudo Ok, Ueda S, Ishikawa A, Matsuyama N, et al. Systemically injected exosomes focused to EGFR ship antitumor microRNA to breast most cancers cells. Mol Ther. 2013;21(1):185–91.
Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. BM mesenchymal stromal cell-derived exosomes facilitate a number of myeloma development. J Clin Make investments. 2013;123(4):1542–55.
Bruno S, Collino F, Deregibus MC, Grange C, Tetta C, Camussi G. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor development. Stem Cells Dev. 2013;22(5):758–71.
Wu S, Ju GQ, Du T, Zhu YJ, Liu GH. Microvesicles derived from human umbilical twine Wharton’s jelly mesenchymal stem cells attenuate bladder tumor cell development in vitro and in vivo. PLoS ONE. 2013;8(4):e61366.
Liang X, Li C, Music J, Liu A, Wang C, Wang W, et al. HucMSC-Exo promote Mucosal Therapeutic in Experimental Colitis by accelerating intestinal stem cells and epithelium regeneration through wnt signaling pathway. Int J Nanomed. 2023;18:2799–818.
Wang D, Zhang W, Zhang C, Wang L, Chen H, Xu J. Exosomal non-coding RNAs have a big impact on tumor metastasis. Mol Ther Nucleic Acids. 2022;29:16–35.
Ding L, Ellis MJ, Li S, Larson DE, Chen Ok, Wallis JW, et al. Genome remodelling in a basal-like breast most cancers metastasis and xenograft. Nature. 2010;464(7291):999–1005.
Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4(6):1116–30.
DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MTW, et al. Tumor grafts derived from ladies with breast most cancers authentically replicate tumor pathology, development, metastasis and illness outcomes. Nat Med. 2011;17(11):1514–20.
Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue useful resource of phenotypically steady, biologically and ethnically various, patient-derived human breast most cancers xenograft fashions. Most cancers Res. 2013;73(15):4885–97.
Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, et al. Affected person-derived xenograft fashions: an rising platform for translational most cancers analysis. Most cancers Discov. 2014;4(9):998–1013.
Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A brand new mannequin of affected person tumor-derived breast most cancers xenografts for preclinical assays. Clin Most cancers Res. 2007;13(13):3989–98.
Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor development however doesn’t trigger tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Most cancers Res. 2012;18(9):2515–25.
Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, et al. A affected person tumor transplant mannequin of squamous cell most cancers identifies PI3K inhibitors as candidate therapeutics in outlined molecular bins. Mol Oncol. 2013;7(4):776–90.
Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, et al. Built-in preclinical and scientific growth of mTOR inhibitors in pancreatic most cancers. Br J Most cancers. 2010;103(5):649–55.
Ding N, Cui XX, Gao Z, Huang H, Wei X, Du Z, et al. A triple mixture of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic most cancers cells and xenograft pancreatic tumors. Int J Oncol. 2014;44(6):2139–45.
